Therapeutic Response

PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma.

Statements

Source and description

Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.